FMP
Oncolytics Biotech Inc.
ONC.TO
TSX
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
0.7 CAD
-0.01 (-1.43%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
31.22M
41.26M
32.14M
34.91M
15.94M
-
-
-
-
-
Total Cash %
100
100
100
100
100
100
100
100
100
Receivables
89.66k
866.05k
521k
15k
68k
-
-
-
-
-
Receivables %
100
100
100
100
100
100
100
100
100
Inventories
-
-
-
-
-
-
-
-
-
-
Inventories %
100
100
100
100
100
100
100
100
100
Payable
-
594k
2.25M
1.08M
1.09M
-
-
-
-
-
Payable %
100
100
100
100
100
100
100
100
100
Cap Ex
-29.3k
-285.95k
-55k
-8k
-239k
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
